Article Text

Download PDFPDF

#748 Evolution of debulking surgeries for advanced-stage ovarian cancer in an ESGO-accredited department: a paradigm of change
  1. Stamatios Petousis,
  2. Chrysoula Margioula-Siarkou,
  3. Frederic Guyon,
  4. Konstantina Boniou,
  5. Angelos Sioutas,
  6. George Mavromatidis,
  7. Pavlos Papakotoulas,
  8. Alexios Papanikolaou and
  9. Konstantinos Dinas
  1. nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece


Introduction/Background Debulking surgery for advanced-stage ovarian cancer is potentially the most challenging surgical procedure in the context of gynaecological oncological care. Such cases are continuously referred to specialized Units and ESGO accreditation may act attractively for patients and referring departments. Main objective of the present study is to report the evolution of debulking surgeries after the first ESGO accreditation of a Northern Greek Gynaecologic Oncology Unit at the end of 2020.

Methodology A prospective observational cohort was performed concerning patients treated with a diagnosis of advanced-stage ovarian cancer. Epidemiological, histopathological and surgical reports of all patients were prospectively recorded in a computerized database, based on the recommendations of ESGO for advanced-stage ovarian cancer surgery. The present study concerns patients treated between 2020–2022. Rate of optimal cytoreduction, primary and interval debulking surgery, histological subtype of patients as well as evolution of number of cases throughout study period were set in the center of our analysis.

Results There were overall 98 patients operated during study period, of which 28 in 2020, 33 in 2021 and 37 in 2022. Mean age of patients was 61.8 years. Overall complete cytoreduction rate was 79.5% (78/98 patients). This rate remained stable during the overall period (82.1% vs. 78.8% vs 78.4% respectively, P=NS). Primary debulking surgery rate was 68.4% (67/98 cases), the rate also remaining stable during the overall period (71.4%, 72.3% and 67.6% respectively, P=NS). Rates of complete cytoreduction were comparable between primary cytoreductive and interval debulking surgeries (79.7% vs. 79.3%, P=NS). The main histopathological diagnosis was high-grade serous carcinoma (66/98 cases, 67.3%). Finally, there was observed an overall 32.4% increase of treated cases between 2020 and 2022.

Conclusion ESGO accreditation for individual fellowship lead to significant increase of advanced-stage ovarian cancer patients treated in our Department, with a relative maintenance and upgrade of provided services level.

Disclosures Authors have nothing to disclose

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.